Novo Nordisk has a range of products relating to diabetes, haemostasis, obesity, growth and menopause. Downloads of the Product Information for these products are available in this section.
Written principally for Healthcare Professionals, the Product Information documents provide prescribing information for each of our products. If you are not a Healthcare Professional, Product Information should be read/discussed in consultation with a Healthcare Professional.
To view these files you need to have Adobe Acrobat Reader installed. If you do not have Adobe Acrobat Reader you can download the software free of charge. Get Acrobat Reader
Important Advance Notice: Upcoming Changes to Novo Nordisk Insulin Product Portfolio
Novo Nordisk has advised the TGA about the planned phase out of Novo Nordisk insulin products, which will occur over the next two years and will focus on older generation products with multiple presentations. This is part of a global insulin portfolio consolidation strategy and is not a result of any safety, efficacy or quality-related concerns.
The table below lists the products and presentations that will be impacted in Australia.
We remain committed to working closely with health authorities, the medical community, and patient advocacy groups, in accordance with local regulations, to ensure that patients have access to the medications they need.
We will provide support materials to healthcare professionals to assist patients transitioning to alternative treatments closer to the timings of each product phase out.
*Based on current forecast and patient demand
**Novo Nordisk informed the TGA, PBAC and healthcare professionals in January 2024 about the discontinuation of Mixtard® 30/70 Penfill® and Innolet®. The discontinuation timing for Mixtard® 30/70 Penfill® has been updated to October 2024 to align with the availability of our remaining supply in the market.
Novo Nordisk has advised the TGA there will be continued, limited intermittent availability of Ozempic® (semaglutide), a medicine approved for use in adults with type 2 diabetes, in Australia until December 2024. This is due to the continued, unprecedented demand for Ozempic® (semaglutide) in Australia and around the world. We are working hard to satisfy demand to the greatest extent possible.
Novo Nordisk continues to expand its global manufacturing capacity to meet the strong demand for Ozempic® (semaglutide) for now and into the future. Our global manufacturing facilities are running 24 hours a day, seven days a week. In 2024, we invested approximately USD6.5 billion to boost our production in Kalundborg, Denmark. This is on top of the USD3.6 billion investments Novo Nordisk made last year.
It’s important to continue to follow the joint guidance issued by the TGA and various professional bodies on this matter, and additional information about Ozempic® (semaglutide) supply on the TGA website.
Novo Nordisk will continue to work with the TGA to provide updates on this matter.